Press release




Biophytis announces the settlement and delivery of its €2.6
million private placement

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA,
CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA


Paris (France) and Cambridge (Massachusetts, USA), March 28, 2025 – 10:00 PM (CET) – Biophytis SA
(Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company
specializing in developing treatments for age-related diseases, announces today the settlement and
delivery of its private placement in the amount of €2,599,979.72 (including the issuance premium), carried
out through the issuance, without preferential subscription rights, of (i) 4,307,614 new ordinary shares of
the Company (the “New Shares”), each accompanied by a share subscription warrant (a “Warrant”)
(together with the New Share, the “ABSA”), and (ii) 5,692,308 prepaid subscription warrants (the “Prepaid
Warrants”), each also accompanied by a Warrant (together, the “Prepaid Units”), as announced on March
26, 2025.

The New Shares have been admitted to trading on Euronext Growth on the same quotation line as the
Company’s already listed shares under ISIN code FR001400OLP5.

The Warrants, which were immediately detached from the New Shares upon issuance, are listed on
Euronext Growth as of today, under ISIN code FR001400YN90.

Maxim Group LLC acted as lead placement agent and Invest Securities as co-placement agent in connection
with the Private Placement.

To the Company’s knowledge, the shareholding structure as of today is as follows (noting that the voting
rights percentages are calculated based on a total number of voting rights on a non-diluted basis of
15,855,851, and corrected from a “material” error in the March 26, 2025 press release, which indicated a
total number of voting rights, on a non-diluted basis, of 15,855,846):




1
Press release




The issue price of one ABSA and one Prepaid Unit, combined with the exercise price of the attached
Warrant and Prepaid Warrant, less the theoretical value of one Warrant, results in a discount of 24.1% (and
not 19.2% as incorrectly stated in the March 26, 2025 press release) relative to the 5-day VWAP, in line
with the maximum discount authorized by the Company’s Ordinary and Extraordinary General Meeting of
Shareholders held on April 2, 2024, pursuant to its third resolution.


2
Press release


About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-
related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in
development for muscular diseases (sarcopenia, Phase 3 ready), and metabolic disorders, notably obesity.
The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and
Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its
ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more
information, visit www.biophytis.com.

Disclaimer

This press release does not constitute an offer to sell or the solicitation of an offer to buy ordinary shares
of the Company, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that
jurisdiction.

This announcement is an advertisement and not a prospectus within the meaning of Regulation (EU)
2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the “Prospectus
Regulation”).

In France, the offer of Biophytis (the “Company”) shares described below will be made exclusively in the
context of a capital increase reserved to the category of beneficiaries, within the meaning of Article L. 225-
138 of the French commercial code, defined in the third resolution of the Company’s ordinary and
extraordinary shareholders’ meeting held on April 2, 2024. It shall not constitute a public offering requiring
the publication of a prospectus to be approved by the Autorité des marchés financiers.

The Company will make available to the public an information document containing the information set
out in Annex IX of the Prospectus Regulation.

With respect to Member States of the European Economic Area, no action has been taken or will be taken
to permit a public offering of the securities referred to in this press release requiring the publication of a
prospectus in any Member State.

Therefore, such securities may not be and shall not be offered in any Member State other than in
accordance with the exemptions of Article 1(4) of the Prospectus Regulation or, otherwise, in cases not
requiring the publication of a prospectus under Article 3 of the Prospectus Regulation and/or the applicable
regulations in such Member State.

This press release and the information it contains are being distributed to and are only intended for persons
who are (x) outside the United Kingdom or (y) in the United Kingdom and are (i) investment professionals
falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005,
as amended (the “Order”), (ii) high net worth entities and other such persons falling within Article 49(2)(a)
to (d) of the Order (“high net worth companies”, “unincorporated associations”, etc.) or (iii) other persons
to whom an invitation or inducement to participate in investment activity (within the meaning of Section
21 of the Financial Services and Market Act 2000) may otherwise lawfully be communicated or caused to

3
Press release


be communicated (all such persons in (y)(i), (y)(ii) and (y)(iii) together being referred to as “Relevant
Persons”). Any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities to
which this press release relates will only be engaged with Relevant Persons. Any person who is not a
Relevant Person should not act or rely on this press release or any of its contents.

This press release may not be distributed, directly or indirectly, in or into the United States. This press
release and the information contained herein does not, and will not, constitute an offer of the Company's
shares for sale or subscription, nor the solicitation of an offer to subscribe or to purchase, such shares in
the United States or any other jurisdiction where restrictions may apply. Securities may not be offered or
sold in the United States absent registration or an exemption from registration under the U.S. Securities
Act of 1933, as amended (the “Securities Act”). The shares of the Company have not been and will not be
registered under the Securities Act, and the Company does not intend to conduct a public offering in the
United States.

The distribution of this press release may be subject to legal or regulatory restrictions in certain
jurisdictions. Any person who comes into possession of this press release must inform him or herself of and
comply with any such restrictions.

Any decision to subscribe for or purchase the shares or other securities of the Company must be made
solely based on information publicly available about the Company. Such information is not the
responsibility of Maxim Group LLC or of All Invest and has not been independently verified by Maxim Group
LLC or All Invest.


Biophytis Contacts

Investor Relations
Investors@biophytis.com

US Investors
Pascal Nigen – Alpha Bronze
pnigen@alphabronzellc.com

Media contacts
Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27
Inès de Mandiargues: ines.demandiargues@taddeo.fr - +33 6 16 16 51 78




4